

- Patel T. Cholangiocarcinoma—controversies and challenges. *Nat Rev Gastroenterol Hepatol* 2011;8:189–200.
- Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. *Clin Gastroenterol Hepatol* 2013;11:13–21.
- Uesaka K, Yasui K, Morimoto T, et al. Visualization of routes of lymphatic drainage of the gallbladder with a carbon particle suspension. *J Am Coll Surg* 1996;183:345–350.
- Shirai Y, Yoshida K, Tsukada K, et al. Identification of the regional lymphatic system of the gallbladder by vital staining. *Br J Surg* 1992;79:659–662.
- DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. *Ann Surg* 2007;245:755–762.
- Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol* 2010;17:1471–1474.
- Patel T. Cholangiocarcinoma. *Nat Clin Pract Gastroenterol Hepatol* 2006;3:33–42.
- Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. *Hepatology* 2011;54:173–184.
- Ben-Menachem T. Risk factors for cholangiocarcinoma. *Eur J Gastroenterol Hepatol* 2007;19:615–617.
- Grange MJ, West J, Solaymani-Dodaran M, et al. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. *Br J Cancer* 2009;100:178–180.
- Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. *Clin Gastroenterol Hepatol* 2007;5:1221–1228.
- Shin HR, Oh JK, Masuyer E, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. *Cancer Sci* 2010;101:579–585.
- Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. *Curr Opin Gastroenterol* 2008;24:349–356.
- Hoceqlouel L, Gervais A. Cholangiocarcinoma and AIDS-related sclerosing cholangitis. *Ann Intern Med* 2000;132:1006–1007.
- Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. *J Hepatol* 2012;57:69–76.
- Li M, Li J, Li P, et al. Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. *J Gastroenterol Hepatol* 2012;27:1561–1568.
- Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. *Gut* 1996;38:610–615.
- Ritchie JK, Allan RN, Macartney J, et al. Biliary tract carcinoma associated with ulcerative colitis. *Q J Med* 1974;43:263–279.
- Ross AP, Braasch JW. Ulcerative colitis and carcinoma of the proximal bile ducts. *Gut* 1973;14:94–97.
- Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. *Hepatology* 2011;54:1842–1852.
- de Groen PC. Cholangiocarcinoma in primary sclerosing cholangitis: who is at risk and how do we screen? *Hepatology* 2000;31:247–248.
- Jan YY, Chen MF, Wang CS, et al. Surgical treatment of hepatolithiasis: long-term results. *Surgery* 1996;120:509–514.
- Hasumi A, Matsui H, Sugioaka A, et al. Precancerous conditions of biliary tract cancer in patients with pancreaticobiliary maljunction: reappraisal of nationwide survey in Japan. *J Hepatobiliary Pancreat Surg* 2000;7:551–555.
- Ono J, Sakoda K, Akita H. Surgical aspect of cystic dilatation of the bile duct. An anomalous junction of the pancreaticobiliary tract in adults. *Ann Surg* 1982;195:203–208.
- Flanigan DP. Biliary carcinoma associated with biliary cysts. *Cancer* 1977;40:880–883.
- Chapman RW. Risk factors for biliary tract carcinogenesis. *Ann Oncol* 1999;10 Suppl 4:308–311.
- Taylor AC, Palmer KR. Caroli's disease. *Eur J Gastroenterol Hepatol* 1998;10:105–108.
- Brandi C, Di Girolamo S, Farioli A, et al. Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis. *Cancer Causes Control* 2013;24:911–918.
- Kumagai S, Kurumatani N, Arimoto A, et al. Cholangiocarcinoma among offset colour proof-printing workers exposed to 1,2-dichloropropane and/or dichloromethane. *Occup Environ Med* 2013;70:508–510.
- Mitacek EJ, Brunneemann KD, Hoffmann D, et al. Volatile nitrosamines and tobacco-specific nitrosamines in the smoke of Thai cigarettes: a risk factor for lung cancer and a suspected risk factor for liver cancer in Thailand. *Carcinogenesis* 1999;20:133–137.
- Kato I, Kido C. Increased risk of death in thorotrast-exposed patients during the late follow-up period. *Jpn J Cancer Res* 1987;78:1187–1192.
- Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. *Gastroenterology* 2005;128:620–626.
- El-Serag HB, Engels EA, Landgren O, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. *Hepatology* 2009;49:116–123.
- Braconi C, Patel T. Cholangiocarcinoma: new insights into disease pathogenesis and biology. *Infect Dis Clin North Am* 2010;24:871–884.
- Sia D, Tovar V, Moeini A, et al. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. *Oncogene* 2013;32:4861–4870.
- Sugawara H, Yasoshima M, Katayanagi K, et al. Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. *Histopathology* 1998;33:145–153.
- Amaya S, Sasaki M, Watanabe Y, et al. Expression of MUC1 and MUC2 and carbohydrate antigen Tn change during malignant transformation of biliary papillomatosis. *Histopathology* 2001;38:550–560.
- Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. *J Clin Oncol* 2010;28:3531–3540.
- Hassid VJ, Orlando FA, Awad ZT, et al. Genetic and molecular abnormalities in cholangiocarcinogenesis. *Anticancer Res* 2009;29:1151–1156.
- Ahrendt SA, Rashid A, Chow JT, et al. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. *J Hepatobiliary Pancreat Surg* 2000;7:426–431.
- O'Dell MR, Huang JL, Whitney-Miller CL, et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. *Cancer Res* 2012;72:1577–1567.
- Aishima SI, Taguchi KI, Sugimachi K, et al. c-erbB-2 and c-MET expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. *Histopathology* 2002;40:269–278.
- Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. *Oncologist* 2012;17:72–79.
- Voss JS, Holtegaard LM, Kerr SE, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. *Hum Pathol* 2013;44:1216–1222.
- Yoon HA, Noh MH, Kim BG, et al. Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. *World J Gastroenterol* 2011;17:4023–4030.
- Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. *Gastroenterology* 2013;144:829–840.
- Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. *Gastroenterology* 2012;142:1021–1031.
- Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. *Curr Opin Gastroenterol* 2012;28:266–272.
- Martin RC, Klimstra DS, Schwartz L, et al. Hepatic intraductal oncocytic papillary carcinoma. *Cancer* 2002;95:2180–2187.
- Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. *AJR Am J Roentgenol* 2003;181:819–827.
- Burke EC, Jarnagin WR, Hochwald SN, et al. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. *Ann Surg* 1998;228:385–394.
- Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. *Hepatology* 2001;33:1353–1357.
- Patel T. Worldwide trends in mortality from biliary tract malignancies. *BMC Cancer* 2002;2:10.
- McLean L, Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. *Liver Int* 2006;26:1047–1053.
- Chen MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. *J Gastroenterol Hepatol* 1999;14:1144–1149.
- Capizzi PJ, Rosen CB, Nagorney DM. Intermittent jaundice by tumor emboli from intrahepatic cholangiocarcinoma. *Gastroenterology* 1992;103:1669–1673.
- Choi BI, Han JK, Shin YM, et al. Peripheral cholangiocarcinoma: comparison of MRI with CT. *Abdom Imaging* 1995;20:357–360.
- Soyer P, Bluemke DA, Hruban RH, et al. Intrahepatic cholangiocarcinoma: findings on spiral CT during arterial portography. *Eur J Radiol* 1994;19:37–42.
- Soyer P, Bluemke DA, Sibert A, et al. MR imaging of intrahepatic cholangiocarcinoma. *Abdom Imaging* 1995;20:126–130.
- Gautier AL, Vilgrain V, Flejou JF, et al. [Imaging of peripheral cholangiocarcinoma. Comparison with pathological anatomy]. *Gastroenterol Clin Biol* 1996;20:139–145.
- Patsenker E, Wilkens L, Banz V, et al. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma. *J Hepatol* 2010;52:362–369.
- Ruillier A, Le Bail B, Fawaz R, et al. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. *Am J Surg Pathol* 2000;24:870–876.
- Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. *Gut* 2002;51:V11–V19.
- Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. *Gut* 2012;61:1657–1669.

65. Goere D, Wagholikar GD, Pessaux P, et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. *Surg Endosc* 2006;20:721–725.
66. Ribero D, Pinna AD, Guglielmi A, et al. Surgical Approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. *Arch Surg* 2012;147:1107–1113.
67. Nakanuma Y, Sasaki M, Ishikawa A, et al. Biliary papillary neoplasm of the liver. *Histol Histopathol* 2002;17:851–861.
68. Poultides GA, Zhu AX, Choti MA, et al. Intrahepatic cholangiocarcinoma. *Surg Clin North Am* 2010;90:817–837.
69. Pascher A, Jonas S, Neuhaus P. Intrahepatic cholangiocarcinoma: indication for transplantation. *J Hepatobiliary Pancreat Surg* 2003;10:282–287.
70. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med* 2010;362:1273–1281.
71. Lee S, Oh SY, Kim BG, et al. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. *Am J Clin Oncol* 2009;32:348–352.
72. Moretto R, Raimondo L, De Stefano A, et al. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience. *Anticancer Drugs* 2013;24:980–985.
73. Nakagawa K, Katayose Y, Unno M. [Efficacy of neoadjuvant chemoradiation therapy for clinical Stage II cholangiocarcinoma as a preoperative diagnosis]. *Gan To Kagaku Ryoho* 2012;39:1945–1947.
74. Katayose Y, Rikiyama T, Motoi F, et al. Phase I trial of neoadjuvant chemoradiation with gemcitabine and surgical resection for cholangiocarcinoma patients (NACRAC study). *Hepatogastroenterology* 2011;58:1866–1872.
75. Arai Y, Totoki Y, Hosoda F, et al. FGFR2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. *Hepatology* 2014;59:1427–1434.
76. Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. *Cancer Discov* 2013;3:636–647.
77. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. *Am J Med* 1965;38:241–256.
78. Lee CC, Wu CY, Chen JT, et al. Comparing combined hepatocellular-cholangiocarcinoma and cholangiocarcinoma: a clinicopathological study. *Hepatogastroenterology* 2002;49:1487–1490.
79. Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. *Gastrointest Endosc* 2002;56:40–47.
80. Hultcrantz R, Olsson R, Danielsson A, et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. *J Hepatol* 1999;30:669–673.
81. Björnsson E, Kilarand A, Olsson R. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. *Liver* 1999;19:501–508.
82. Chen CY, Shiesh SC, Tsao HC, et al. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma—the influence of sampling time and hepatolithiasis. *Hepatogastroenterology* 2002;49:616–620.
83. Ozkan H, Kaya M, Cengiz A. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. *Hepatogastroenterology* 2003;50:1669–1674.
84. Carpelan-Holmstrom M, Louhimo J, Stenman UH, et al. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. *Anticancer Res* 2002;22:2311–2316.
85. Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. *Semin Liver Dis* 2004;24:139–154.
86. Enjoji M, Nakashima M, Yamaguchi K, et al. Significance of RCAS1 antigen in hepatocellular, cholangiocellular and pancreatic carcinomas. *J Gastroenterol Hepatol* 2005;20:1143–1148.
87. Wongkham S, Sheehan JK, Boonla C, et al. Serum MUC5AC mucin as a potential marker for cholangiocarcinoma. *Cancer Lett* 2003;195:93–99.
88. Hatzaras I, Schmidt C, Muscarella P, et al. Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies. *HPB (Oxford)* 2010;12:134–138.
89. Blumgart LH, Stain SC. Surgical treatment of cholangiocarcinoma. *Cancer Treat Res* 1994;69:75–96.
90. Masselli G, Gualdi G. Hilar cholangiocarcinoma: MRI/MRCP in staging and treatment planning. *Abdom Imaging* 2008;33:444–451.
91. Masselli G, Manfredi R, Vecchioli A, et al. MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: correlation with surgical and pathologic findings. *Eur Radiol* 2008;18:2213–2221.
92. Lee MG, Park KB, Shin YM, et al. Preoperative evaluation of hilar cholangiocarcinoma with contrast-enhanced three-dimensional fast imaging with steady-state precession magnetic resonance angiography: comparison with intraarterial digital subtraction angiography. *World J Surg* 2003;27:278–283.
93. Chen YK, Parsi MA, Binmoeller KF, et al. Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). *Gastrointest Endosc* 2011;74:805–814.
94. Fukuda Y, Tsuyuguchi T, Sakai Y, et al. Diagnostic utility of peroral cholangioscopy for various bile-duct lesions. *Gastrointest Endosc* 2005;62:374–382.
95. Shah RJ, Langer DA, Antillon MR, et al. Cholangioscopy and cholangioscopic forceps biopsy in patients with indeterminate pancreaticobiliary pathology. *Clin Gastroenterol Hepatol* 2006;4:219–225.
96. Itoi T, Osanai M, Igarashi Y, et al. Diagnostic peroral video cholangioscopy is an accurate diagnostic tool for patients with bile duct lesions. *Clin Gastroenterol Hepatol* 2010;8:934–938.
97. Fishman DS, Tarnasky PR, Patel SN, et al. Management of pancreaticobiliary disease using a new intra-ductal endoscope: the Texas experience. *World J Gastroenterol* 2009;15:1353–1358.
98. Meinung A, Chen YK, Pleskow D, et al. Direct visualization of indeterminate pancreaticobiliary strictures with probe-based confocal laser endomicroscopy: a multicenter experience. *Gastrointest Endosc* 2011;74:961–968.
99. Stavropoulos S, Larghi A, Verna E, et al. Intraductal ultrasound for the evaluation of patients with biliary strictures and no abdominal mass on computed tomography. *Endoscopy* 2005;37:715–721.
100. Verbeek PC, van Leeuwen DJ, de Wit LT, et al. Benign fibrosing disease at the hepatic confluence mimicking Klatskin tumors. *Surgery* 1992;112:866–871.
101. Juntermanns B, Kaiser GM, Reis H, et al. Klatskin-mimicking lesions: still a diagnostic and therapeutic dilemma? *Hepatogastroenterology* 2011;58:265–269.
102. Wetter LA, Ring EJ, Pellegrini CA, Way LW. Differential diagnosis of sclerosing cholangiocarcinomas of the common hepatic duct (Klatskin tumors). *Am J Surg* 1991;161:57–62.
103. de Bellis M, Sherman S, Fogel EL, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 2). *Gastrointest Endosc* 2002;56:720–730.
104. De Bellis M, Sherman S, Fogel EL, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 1). *Gastrointest Endosc* 2002;56:552–561.
105. Fogel EL, deBellis M, McHenry L, et al. Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study. *Gastrointest Endosc* 2006;63:71–77.
106. Ferrari Junior AP, Lichtenstein DR, Slivka A, et al. Brush cytology during ERCP for the diagnosis of biliary and pancreatic malignancies. *Gastrointest Endosc* 1994;40:140–145.
107. Jamagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. *Ann Surg* 2001;234:507–517.
108. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. *Ann Surg* 1992;215:31–38.
109. Paul A, Kaiser GM, Molmenti EP, et al. Klatskin tumors and the accuracy of the Bismuth-Corlette classification. *Am Surg* 2011;77:1695–1699.
110. Deoliveira ML, Schulick RD, Nimura Y, et al. New staging system and a registry for perihilar cholangiocarcinoma. *Hepatology* 2011;53:1363–1371.
111. Neumaier CE, Bertolotto M, Perrone R, et al. Staging of hilar cholangiocarcinoma with ultrasound. *J Clin Ultrasound* 1995;23:173–178.
112. Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. *Gastroenterology* 2012;143:88–98.
113. Murad SD, Heimbach JK, Gores GJ, et al. Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation. *Liver Transpl* 2013;19:521–528.
114. Hassoun Z, Gores GJ, Rosen CB. Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. *Surg Oncol Clin N Am* 2002;11:909–921.
115. Heimbach JK, Haddock MG, Alberts SR, et al. Transplantation for hilar cholangiocarcinoma. *Liver Transpl* 2004;10:S65–S68.
116. Shimoda M, Farmer DG, Colquhoun SD, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. *Liver Transpl* 2001;7:1023–1033.
117. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. *Transplantation* 2000;69:1633–1637.
118. Jonas S, Mittler J, Pascher A, et al. Extended indications in living-donor liver transplantation: bile duct cancer. *Transplantation* 2005;80:S101–S104.
119. Lillemoen KD, Cameron JL. Surgery for hilar cholangiocarcinoma: the Johns Hopkins approach. *J Hepatobiliary Pancreat Surg* 2000;7:115–121.
120. Hochwald SN, Burke EC, Jamagin WR, et al. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. *Arch Surg* 1999;134:261–266.
121. Sakata J, Shirai Y, Wakai T, et al. Catheter tract implantation metastases associated with percutaneous biliary drainage for extrahepatic cholangiocarcinoma. *World J Gastroenterol* 2005;11:7024–7027.
122. Ferrero A, Lo Tesoriere R, Viganò L, et al. Preoperative biliary drainage increases infectious complications after hepatectomy for proximal bile duct tumor obstruction. *World J Surg* 2009;33:318–325.
123. Liu F, Li Y, Wei Y, et al. Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. *Dig Dis Sci* 2011;56:663–672.
124. Sewnath ME, Karsten TM, Prins MH, et al. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. *Ann Surg* 2002;236:17–27.
125. Tabata M, Kawarada Y, Yokoi H, et al. Surgical treatment for hilar cholangiocarcinoma. *J Hepatobiliary Pancreat Surg* 2000;7:148–154.
126. Nimura Y, Kamiya J, Kondo S, et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. *J Hepatobiliary Pancreat Surg* 2000;7:155–162.

127. Callery MP, Strasberg SM, Doherty GM, et al. Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy. *J Am Coll Surg* 1997;185:33–39.
128. Ito K, Ito H, Allen PJ, et al. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. *Ann Surg* 2010;251:675–681.
129. Rocha FC, Matsuo K, Blumgart LH, et al. Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience. *J Hepatobiliary Pancreat Sci* 2010;17:490–496.
130. Nagino M, Kamiya J, Uesaka K, et al. Complications of hepatectomy for hilar cholangiocarcinoma. *World J Surg* 2001;25:1277–1283.
131. Bengmark S, Ekberg H, Evander A, et al. Major liver resection for hilar cholangiocarcinoma. *Ann Surg* 1988;207:120–125.
132. Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. *Arch Surg* 1995;130:270–276.
133. Pinson CW, Rossi RL. Extended right hepatic lobectomy, left hepatic lobectomy, and skeletonization resection for proximal bile duct cancer. *World J Surg* 1988;12:52–59.
134. Iwasaki Y, Okamura T, Ozaki A, et al. Surgical treatment for carcinoma at the confluence of the major hepatic ducts. *Surg Gynecol Obstet* 1986;162:457–464.
135. Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. *Ann Surg* 1996;223:384–394.
136. Nagorney DM, Donohue JH, Farnell MB, et al. Outcomes after curative resections of cholangiocarcinoma. *Arch Surg* 1993;128:871–877.
137. Otani K, Chijiwa K, Kai M, et al. Outcome of surgical treatment of hilar cholangiocarcinoma. *J Gastrointest Surg* 2008;12:1033–1040.
138. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. *Ann Surg* 1996;224:463–473.
139. Klemptner J, Ridder GJ, von Wasielewski R, et al. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. *J Clin Oncol* 1997;15:947–954.
140. Lee SW, Kim HJ, Park JH, et al. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. *J Gastroenterol* 2010;45:560–566.
141. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. *Cancer* 2002;95:1685–1695.
142. Hii MW, Gibson RN, Speer AG, et al. Role of radiology in the treatment of malignant hilar biliary strictures 2: 10 years of single-institution experience with percutaneous treatment. *Australas Radiol* 2003;47:393–403.
143. Kang MJ, Choi YS, Jang JY, et al. Catheter tract recurrence after percutaneous biliary drainage for hilar cholangiocarcinoma. *World J Surg* 2013;37:437–442.
144. Jamagin WR, Burke E, Powers C, et al. Intrahepatic biliary enteric bypass provides effective palliation in selected patients with malignant obstruction at the hepatic duct confluence. *Am J Surg* 1998;175:453–460.
145. Witzigmann H, Lang H, Lauer H. Guidelines for palliative surgery of cholangiocarcinoma. *HPB (Oxford)* 2008;10:154–160.
146. Zhang BH, Cheng QB, Luo XJ, et al. Surgical therapy for hilar cholangiocarcinoma: analysis of 198 cases. *Hepatobiliary Pancreat Dis Int* 2006;5:278–282.
147. Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for non-resectable cholangiocarcinoma: a randomized prospective study. *Gastroenterology* 2003;125:1355–1363.
148. Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. *Am J Gastroenterol* 2005;100:2426–2430.
149. Cheon YK, Cho YD, Baek SH, et al. [Comparison of survival of advanced hilar cholangiocarcinoma after biliary drainage alone versus photodynamic therapy with external drainage]. *Korean J Gastroenterol* 2004;44:280–287.
150. Leggett CL, Gorospe EC, Murad MH, et al. Photodynamic therapy for unresectable cholangiocarcinoma: a comparative effectiveness systematic review and meta-analysis. *Photodiagnosis Photodyn Ther* 2012;9:189–195.
151. Ohnishi H, Asada M, Shichijo Y, et al. External radiotherapy for biliary depression of hilar cholangiocarcinoma. *Hepatogastroenterology* 1995;42:265–268.
152. Leung J, Guiney M, Das R. Intraluminal brachytherapy in bile duct carcinomas. *Aust N Z J Surg* 1996;66:74–77.
153. Kuвшinoff BW, Armstrong JC, Fong Y, et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. *Br J Surg* 1995;82:1522–1525.
154. Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. *Ann Surg* 1995;221:788–797.
155. Kopek N, Holt MI, Hansen AT, et al. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. *Radiother Oncol* 2010;94:47–52.
156. Momm F, Schubert E, Henne K, et al. Stereotactic fractionated radiotherapy for Klatskin tumours. *Radiother Oncol* 2010;95:99–102.
157. Steel AW, Postgate AJ, Khorsandi S, et al. Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. *Gastrointest Endosc* 2011;73:149–153.
158. Yamao K, Hara K, Mizuno N, et al. EUS-guided biliary drainage. *Gut Liver* 2010;4 Suppl 1:S67–S75.
159. Yamao K, Bhatia V, Mizuno N, et al. EUS-guided choledochoduodenostomy for palliative biliary drainage in patients with malignant biliary obstruction: results of long-term follow-up. *Endoscopy* 2008;40:340–342.
160. Park do H, Koo JE, Oh J, et al. EUS-guided biliary drainage with one-step placement of a fully covered metal stent for malignant biliary obstruction: a prospective feasibility study. *Am J Gastroenterol* 2009;104:2168–2174.
161. Kahaleh M, Hernandez AJ, Tokar J, et al. EUS-guided pancreaticogastrostomy: analysis of its efficacy to drain inaccessible pancreatic ducts. *Gastrointest Endosc* 2007;65:224–230.
162. Maranki J, Hernandez AJ, Arslan B, et al. Interventional endoscopic ultrasound-guided cholangiography: long-term experience of an emerging alternative to percutaneous transhepatic cholangiography. *Endoscopy* 2009;41:532–538.
163. Nichols JC, Gores GJ, LaRusso NF, et al. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. *Mayo Clin Proc* 1993;68:874–879.
164. Ramage JK, Donaghy A, Farrant JM, et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. *Gastroenterology* 1995;108:865–869.
165. Stamatakis JD, Howard ER, Williams R. Benign inflammatory tumour of the common bile duct. *Br J Surg* 1979;66:257–258.
166. Tio TL, Cheng J, Wijers OB, et al. Endosonographic TNM staging of extrahepatic bile duct cancer: comparison with pathological staging. *Gastroenterology* 1991;100:1351–1361.
167. Kluge R, Schmidt F, Caca K, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. *Hepatology* 2001;33:1029–1035.
168. Warshaw AL, Tepper JE, Shipley WU. Laparoscopy in the staging and planning of therapy for pancreatic cancer. *Am J Surg* 1986;151:76–80.
169. John TG, Greig JD, Crosbie JL, et al. Superior staging of liver tumors with laparoscopy and laparoscopic ultrasound. *Ann Surg* 1994;220:711–719.
170. McLeod RS, Taylor BR, O'Connor BI, et al. Quality of life, nutritional status, and gastrointestinal hormone profile following the Whipple procedure. *Am J Surg* 1995;169:179–185.
171. Strasberg SM, Drebiln JA, Soper NJ. Evolution and current status of the Whipple procedure: an update for gastroenterologists. *Gastroenterology* 1997;113:983–994.
172. Cheng Q, Luo X, Zhang B, et al. Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases. *Ann Surg Oncol* 2007;14:1212–1219.
173. Murakami Y, Uemura K, Hayashidani Y, et al. Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis. *World J Surg* 2007;31:337–342.
174. Prat F, Chapat O, Ducot B, et al. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. *Gastrointest Endosc* 1998;47:1–7.
175. Smith AC, Dowsett JF, Russell RC, et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. *Lancet* 1994;344:1655–1660.
176. Glenn F, Hays DM. The scope of radical surgery in the treatment of malignant tumors of the extrahepatic biliary tract. *Surg Gynecol Obstet* 1954;99:529–541.
177. Rudolph R, Cohen JJ. Cancer of the gallbladder in an 11-yr-old Navajo girl. *J Pediatric Surg* 1972;7:66–67.
178. De Aretxabala X, Roa I, Araya JC, et al. Gallbladder cancer in patients less than 40 years old. *Br J Surg* 1994;81:111.
179. de Aretxabala XA, Roa IS, Burgos LA, et al. Curative resection in potentially resectable tumours of the gallbladder. *Eur J Surg* 1997;163:419–426.
180. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. *Int J Cancer* 2006;118:1591–1602.
181. Saika K, Matsuda T. Comparison of time trends in gallbladder cancer mortality (1990-2006) between countries based using the WHO mortality database. *Jpn J Clin Oncol* 2010;40:374–375.
182. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. *Cancer* 1995;75:171–190.
183. Strom BL, Soloway RD, Rios-Dalenz JL, et al. Risk factors for gallbladder cancer. An international collaborative case-control study. *Cancer* 1995;76:1747–1756.
184. Nervi F, Duarte I, Gomez G, et al. Frequency of gallbladder cancer in Chile, a high-risk area. *Int J Cancer* 1988;41:657–660.
185. Strom BL, Nelson WL, Henson DE, et al. Carcinoma of the gallbladder. In: Cohen S, Soloway RD, eds. *Gallstones*. New York: Churchill Livingstone; 1985: 275.
186. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. *CA Cancer J Clin* 2001;51:349–364.
187. Serra I, Calvo A, Baez S, et al. Risk factors for gallbladder cancer. An international collaborative case-control study. *Cancer* 1996;78:1515–1517.
188. Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. *Surg Gynecol Obstet* 1978;147:929–942.
189. Maringhini A, Moreau JA, Melton LJ 3rd, et al. Gallstones, gallbladder cancer, and other gastrointestinal malignancies. An epidemiologic study in Rochester, Minnesota. *Ann Intern Med* 1987;107:30–35.
190. Strom BL, Soloway RD, Rios-Dalenz J, et al. Biochemical epidemiology of gallbladder cancer. *Hepatology* 1996;23:1402–1411.

191. Diehl AK. Gallstone size and the risk of gallbladder cancer. *JAMA* 1983;250:2323–2326.
192. Fernandez E, La Vecchia C, D'Avanzo B, et al. Family history and the risk of liver, gallbladder, and pancreatic cancer. *Cancer Epidemiol Biomarkers Prev* 1994;3:209–212.
193. Srivastava K, Srivastava A, Mittal B. Polymorphisms in ERCC2, MSH2, and OGG1 DNA repair genes and gallbladder cancer risk in a population of Northern India. *Cancer* 2010;116:3160–3169.
194. Chijiwa K, Kimura H, Tanaka M. Malignant potential of the gallbladder in patients with anomalous pancreaticobiliary ductal junction. The difference in risk between patients with and without choledochal cyst. *Int Surg* 1995;80:61–64.
195. Todani T, Toki A. [Cancer arising in choledochal cyst and management]. *Nihon Geka Gakkai zasshi* 1996;97:594–598.
196. Tokiwa K, Iwai N. Early mucosal changes of the gallbladder in patients with anomalous arrangement of the pancreaticobiliary duct. *Gastroenterology* 1996;110:1614–1618.
197. Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: a relationship revisited. *Surgery* 2001;129:699–703.
198. Towfigh S, McFadden DW, Cortina GR, et al. Porcelain gallbladder is not associated with gallbladder carcinoma. *Am Surg* 2001;67:7–10.
199. Welton JC, Marr JS, Friedman SM. Association between hepatobiliary cancer and typhoid carrier state. *Lancet* 1979;1:791–794.
200. Matsukura N, Yokomuro S, Yamada S, et al. Association between *Helicobacter bilis* in bile and biliary tract malignancies: H. bilis in bile from Japanese and Thai patients with benign and malignant diseases in the biliary tract. *Jpn J Cancer Res* 2002;93:842–847.
201. Mishra RR, Tewari M, Shukla HS. *Helicobacter* species and pathogenesis of gallbladder cancer. *Hepatobiliary Pancreat Dis Int* 2010;9:129–134.
202. Neugut AI, Wylie P, Brandt-Rauf PW. Occupational cancers of the gastrointestinal tract. II. Pancreas, liver, and biliary tract. *Occup Med* 1987;2:137–153.
203. Broden G, Bengtsson L. Biliary carcinoma associated with methyldopa therapy. *Acta Chir Scand Suppl* 1980;500:7–12.
204. Lowenfels AB, Norman J. Isoniazid and bile duct cancer. *JAMA* 1978;240:434–435.
205. Ellis EF, Gordon PR, Gottlieb LS. Oral contraceptives and cholangiocarcinoma. *Lancet* 1978;1:207.
206. Kimura W, Nagai H, Kuroda A, et al. Clinicopathologic study of asymptomatic gallbladder carcinoma found at autopsy. *Cancer* 1989;64:98–103.
207. Perpetuo MD, Valdivieso M, Heilbrun LK, et al. Natural history study of gallbladder cancer: a review of 36 years experience at M. D. Anderson Hospital and Tumor Institute. *Cancer* 1978;42:330–335.
208. Okabayashi T, Sun ZL, Montgomey RA, et al. Surgical outcome of carcinosarcoma of the gall bladder: a review. *World J Gastroenterol* 2009;15:4877–4882.
209. Mano H, Roa I, Araya JC, et al. Comparison of mutagenic activity of bile between Chilean and Japanese female patients having cholelithiasis. *Mutat Res* 1996;371:73–77.
210. Kowalewski K, Todd EF. Carcinoma of the gallbladder induced in hamsters by insertion of cholesterol pellets and feeding dimethylnitrosamine. *Proc Soc Exp Biol Med* 1971;136:482–486.
211. Diehl AK, Beral V. Cholecystectomy and changing mortality from gallbladder cancer. *Lancet* 1981;2:187–189.
212. Albores-Saavedra J, Henson DE. *Atlas of Tumor Pathology, 2nd Series, Fascicle 22: Tumors of the Gallbladder and Extrahepatic Bile Ducts*. Washington DC: Armed Forces Institute of Pathology; 1986.
213. Roa I, Araya JC, Villaseca M, et al. Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression. *Gastroenterology* 1996;111:232–236.
214. Itoi T, Watanabe H, Ajioka Y, et al. APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. *Pathol Int* 1996;46:333–340.
215. Wistuba II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. *J Hepatobiliary Pancreat Surg* 1999;6:237–244.
216. Imai M, Hoshi T, Ogawa K. K-ras codon 12 mutations in biliary tract tumors detected by polymerase chain reaction denaturing gradient gel electrophoresis. *Cancer* 1994;73:2727–2733.
217. Saetta AA, Papanastasiou P, Michalopoulos NV, et al. Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. *Virchows Arch* 2004;445:179–182.
218. Leone F, Cavalloni G, Pignochino Y, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. *Clinical Cancer Research* 2006;12:1680–1685.
219. Nakazawa K, Dobashi Y, Suzuki S, et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-MET in biliary tract cancers. *J Pathol* 2005;206:356–365.
220. Koda M, Yashima K, Kawaguchi K, et al. Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma. *Cancer Lett* 2003;199:131–138.
221. Riquelme E, Tang M, Baez S, et al. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. *Cancer Lett* 2007;250:100–106.
222. Hanada K, Itoh M, Fujii K, et al. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. *Cancer* 1996;77:452–458.
223. Kaneko K, Ando H, Umeda T, et al. A new model for pancreaticobiliary maljunction without bile duct dilatation: demonstration of cell proliferation in the gallbladder epithelium. *J Surg Res* 1996;60:115–121.
224. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nature reviews. *Cancer* 2004;4:695–706.
225. Kamisawa T, Tu Y, Kuwata G, et al. Biliary carcinoma risk in patients with pancreaticobiliary maljunction and the degree of extrahepatic bile duct dilatation. *Hepatogastroenterology* 2006;53:816–818.
226. Mohandas KM, Patil PS. Cholecystectomy for asymptomatic gallstones can reduce gall bladder cancer mortality in northern Indian women. *Indian J Gastroenterol* 2006;25:147–151.
227. Shukla VK, Gurubachan, Sharma D, et al. Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder. *Trop Gastroenterol* 2006;27:160–165.
228. Wibbenmeyer LA, Sharafuddin MJ, Wolverson MK, et al. Sonographic diagnosis of unsuspected gallbladder cancer: imaging findings in comparison with benign gallbladder conditions. *AJR Am J Roentgenol* 1995;165:1169–1174.
229. Pandey M, Sood BP, Shukla RC, et al. Carcinoma of the gallbladder: role of sonography in diagnosis and staging. *J Clin Ultrasound* 2000;28:227–232.
230. Schwartz LH, Coakley FV, Sun Y, et al. Neoplastic pancreaticobiliary duct obstruction: evaluation with breath-hold MR cholangiopancreatography. *AJR Am J Roentgenol* 1998;170:1491–1495.
231. Ohtani T, Shirai Y, Tsukada K, et al. Spread of gallbladder carcinoma: CT evaluation with pathologic correlation. *Abdom Imaging* 1996;21:195–201.
232. Rodriguez-Fernandez A, Gomez-Rio M, Medina-Benitez A, et al. Application of modern imaging methods in diagnosis of gallbladder cancer. *J Surg Oncol* 2006;93:650–664.
233. Akosa AB, Barker F, Desa L, et al. Cytologic diagnosis in the management of gallbladder carcinoma. *Acta Cytologica* 1995;39:494–498.
234. Meara RS, Jhala D, Eloubeidi MA, et al. Endoscopic ultrasound-guided FNA biopsy of bile duct and gallbladder: analysis of 53 cases. *Cytopathology* 2006;17:42–49.
235. Nevin JE, Moran TJ, Kay S, et al. Carcinoma of the gallbladder: staging, treatment, and prognosis. *Cancer* 1976;37:141–148.
236. Tsukada K, Hatakeyama K, Kurosaki I, et al. Outcome of radical surgery for carcinoma of the gallbladder according to the TNM stage. *Surgery* 1996;120:816–821.
237. Johnstone PA, Rohde DC, Swartz SE, et al. Port site recurrences after laparoscopic and thoracoscopic procedures in malignancy. *J Clin Oncol* 1996;14:1950–1956.
238. Copher JC, Rogers JJ, Dalton ML. Trocar-site metastasis following laparoscopic cholecystectomy for unsuspected carcinoma of the gallbladder. Case report and review of the literature. *Surg Endosc* 1995;9:348–350.
239. Doule M, King G, Thomas WM, et al. The movement of mucosal cells of the gallbladder within the peritoneal cavity during laparoscopic cholecystectomy. *Surg Endosc* 1996;10:1092–1094.
240. Toda K, Souda S, Yoshikawa Y, et al. Significance of laparoscopic excisional biopsy for polypoid lesions of the gallbladder. *Surg Laparosc Endosc* 1995;5:267–271.
241. Kubota K, Bandai Y, Noie T, et al. How should polypoid lesions of the gallbladder be treated in the era of laparoscopic cholecystectomy? *Surgery* 1995;117:481–487.
242. Wu SS, Lin KC, Soon MS, et al. Ultrasound-guided percutaneous transhepatic fine needle aspiration cytology study of gallbladder polypoid lesions. *Am J Gastroenterol* 1996;91:1591–1594.
243. Onoyama H, Yamamoto M, Tseng A, et al. Extended cholecystectomy for carcinoma of the gallbladder. *World J Surg* 1995;19:758–763.
244. Chao TC, Wang CS, Jeng LB, et al. Primary carcinoma of the gallbladder in Taiwan. *J Surg Oncol* 1996;61:49–55.
245. Ruckert JC, Ruckert RL, Cellert K, et al. Surgery for carcinoma of the gallbladder. *Hepatogastroenterology* 1996;43:527–533.
246. Miyazaki M, Itoh H, Ambiru S, et al. Radical surgery for advanced gallbladder carcinoma. *Br J Surg* 1996;83:478–481.
247. Hatfield AR, Tobias R, Terblanche J, et al. Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial. *Lancet* 1982;2:896–899.
248. McPherson GA, Benjamin IS, Hodgson HJ, et al. Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial. *Br J Surg* 1984;71:371–375.
249. Pitt HA, Gomes AS, Lois JF, et al. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? *Ann Surg* 1985;201:545–553.
250. Kresl JJ, Schild SE, Henning GT, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. *Int J Radiat Oncol Biol Phys* 2002;52:167–175.
251. Makela JT, Kairaluoma MI. Superselective intra-arterial chemotherapy with mitomycin for gallbladder cancer. *Br J Surg* 1993;80:912–915.
252. Uno T, Itami J, Aruga M, et al. Primary carcinoma of the gallbladder: role of external beam radiation therapy in patients with locally advanced tumor. *Strahlenther Onkol* 1996;172:496–500.
253. Todoroki T, Iwasaki Y, Orii K, et al. Resection combined with intraoperative radiation therapy (IORT) for stage IV (TNM) gallbladder carcinoma. *World J Surg* 1991;15:357–366.
254. Eckel F, Brunner T, Jelic S, Grp EGW. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2011;22:vi40–vi44.